ReviewAnnals of internal medicine2020
Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review.
Review in Annals of internal medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 346 papers, 6 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
346 citing papers in PubMed, 6 syntheses or guidelines pooled it, 647 citations in OpenAlex.
- Sensitivity of gargle samples compared to swabs for SARS-CoV-2 detection with nucleic acid amplification testing: a systematic review and meta-analysis.Virology journal · 2026Pooled it
- Pooled it
- When to test for COVID-19 using real-time reverse transcriptase polymerase chain reaction: a systematic review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- SARS-CoV-2 saliva testing using RT-PCR: a systematic review.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022Pooled it
- Meta-analysis of the robustness of COVID-19 diagnostic kit performance during the early pandemic.BMJ open · 2022Pooled it
- Evaluation of the diagnostic accuracy of COVID-19 antigen tests: A systematic review and meta-analysis.Journal of the Chinese Medical Association : JCMA · 2021Pooled it
- Characterization of the Human Oropharyngeal Microbiomes in SARS-CoV-2 Infection and Recovery Patients.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Trial
- Identification of a Conserved Linear Epitope in SARS-CoV-2 Nucleocapsid Protein Recognized by Monoclonal Antibody N179.Viruses · 2026Article
- Interactys-AI: Toward AI-Driven Structural Mapping of Virus-Host Interfaces for Antiviral Repurposing and Pandemic Preparedness.Biomolecules · 2026Review
- Contribution ofCurrent issues in molecular biology · 2025Review
- Predicting Short-Term Outcome of COVID-19 Pneumonia Using Deep Learning-Based Automatic Detection Algorithm Analysis of Serial Chest Radiographs.Bioengineering (Basel, Switzerland) · 2025Article
- Next-Generation Nucleic Acid-Based Diagnostics for Viral Pathogens: Lessons Learned from the SARS-CoV-2 Pandemic.Microorganisms · 2025Review
- Anti-Cancer Drugs: Trends and Insights from PubMed Records.Pharmaceutics · 2025Review
- Review
- Laboratory readiness and genomic surveillance of Covid-19 in the capital of Brazil.PLOS global public health · 2025Article
- An EEG-based analysis of the effects of different music genres on driving stress.Frontiers in human neuroscience · 2025Article
- Determinants of SARS-CoV-2 infection across three sentinels sites in Benin during 2021: A multicentric surveillance study.PLOS global public health · 2025Article
- Multidrug resistantCurrent research in microbial sciences · 2025Review
- Factors Affecting Procedural Pain and Discomfort Experienced by Individuals During Nasopharyngeal Swabbing: A Cross-Sectional Study.Florence Nightingale journal of nursing · 2024Article
- COVID-19 severity and corticosteroid treatment have minimal effect on specific antibody production.BMC infectious diseases · 2024Article
286 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 7 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diagnostic testing to identify persons infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-19 that began in late 2019. In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies. In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons. Real-time reverse transcriptase polymerase chain reaction-based assays performed in a laboratory on respiratory specimens are the reference standard for COVID-19 diagnostics. However, point-of-care technologies and serologic immunoassays are rapidly emerging. Although excellent tools exist for the diagnosis of symptomatic patients in well-equipped laboratories, important gaps remain in screening asymptomatic persons in the incubation phase, as well as in the accurate determination of live viral shedding during convalescence to inform decisions to end isolation. Many affluent countries have encountered challenges in test delivery and specimen collection that have inhibited rapid increases in testing capacity. These challenges may be even greater in low-resource settings. Urgent clinical and public health needs currently drive an unprecedented global effort to increase testing capacity for SARS-CoV-2 infection. Here, the authors review the current array of tests for SARS-CoV-2, highlight gaps in current diagnostic capacity, and propose potential solutions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.